SEC Form 4 · accession 0001140361-17-041597
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter C Farrell
Director
Period of report
Nov 6, 2017
Accepted (ET)
Nov 8, 2017 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Nov 6, 2017 | M | 20,000 | $27.58 | A | 314,800 | D | |
| ResMed Common StockF2 | Nov 6, 2017 | S | 18,000 | $83.497 | D | 296,800 | D | |
| ResMed Common StockF3 | Nov 6, 2017 | S | 2,000 | $83.817 | D | 294,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resmed Stock Option PlanF4 | $27.58 | Nov 6, 2017 | M | 20,000 | D | Nov 11, 2012 | Nov 16, 2018 | ResMed Common Stock | 20,000 | 82,460 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2This transaction was executed in multiple trades at prices ranging from 82.75 to 83.75. The price reported above represents the weighted average sales price.
- F3This transaction was executed in multiple trades at prices ranging from $83.76 to $83.93. The price reported above reflects the weighted average sale price.
- F4Represents date options first became exercisable. Options vested 1/4 per year.